Charles Duncan
Stock Analyst at Cantor Fitzgerald
(4.08)
# 501
Out of 4,944 analysts
226
Total ratings
42.01%
Success rate
15.36%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $4.29 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $25.13 | +11.42% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $117.12 | +28.07% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $109.39 | +39.87% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $12.56 | +11.46% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $40.30 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $14.39 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $16.91 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $36.67 | +58.17% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $28.63 | +50.19% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $36.88 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.05 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $131.62 | +17.76% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $12.59 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $14.81 | +136.33% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.36 | +198.17% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.60 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.22 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.97 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.05 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $20.19 | +68.40% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $30.09 | +66.17% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $6.68 | -25.15% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.38 | +955.97% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.98 | +307.71% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $37.67 | +53.97% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $1.70 | +64,605.88% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $3.65 | +2,091.78% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.11 | +170.27% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $10.56 | +4.17% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $9.11 | +31.72% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $8.85 | +1,798.31% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.12 | +843.40% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $14.03 | +1,325.52% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $0.86 | +366.20% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $2.28 | +952.63% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.70 | +8,370.59% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.43 | +179.72% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $65.13 | -40.12% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $72.80 | -79.40% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.54 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $3.74 | +4,712.83% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.29
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $25.13
Upside: +11.42%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $117.12
Upside: +28.07%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $109.39
Upside: +39.87%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $12.56
Upside: +11.46%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $40.30
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.39
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.91
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $36.67
Upside: +58.17%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $28.63
Upside: +50.19%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $36.88
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.05
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $131.62
Upside: +17.76%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.59
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $14.81
Upside: +136.33%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.36
Upside: +198.17%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.60
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.22
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.97
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.05
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $20.19
Upside: +68.40%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $30.09
Upside: +66.17%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $6.68
Upside: -25.15%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.38
Upside: +955.97%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.98
Upside: +307.71%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $37.67
Upside: +53.97%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $1.70
Upside: +64,605.88%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $3.65
Upside: +2,091.78%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.11
Upside: +170.27%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $10.56
Upside: +4.17%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $9.11
Upside: +31.72%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $8.85
Upside: +1,798.31%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.12
Upside: +843.40%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $14.03
Upside: +1,325.52%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $0.86
Upside: +366.20%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $2.28
Upside: +952.63%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.70
Upside: +8,370.59%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.43
Upside: +179.72%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $65.13
Upside: -40.12%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $72.80
Upside: -79.40%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.54
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $3.74
Upside: +4,712.83%